Immunotherapy for castration-resistant prostate cancer has continued to be an area of active research over the last several years. The enthusiasm of this approach has been based on the assumption of better tolerability and that using the body's own immune system may be more effective than either hormonal or chemotherapy. Sipuleucel-T, a dendritic cellbased vaccine, is the only approved agent in this class for the management of castrate-resistant prostate cancer. Although sipuleucel-T increases overall survival without any significant changes in progression-free survival, other forms of immunotherapy such as PSA-TRICOM, ipilimumab, and chimeric antigen receptor T cell therapy are in advanced stages of clinical development. Immune biomarkers are being developed to assess response to these treatments and also to understand how the immune system responds to these respective therapies. Combinations of immunotherapy with androgen deprivation, radiation therapy, and chemotherapy have also been explored with varying results. This review discusses the mechanisms, key preclinical and clinical data, and perspectives for immunotherapeutic agents in the treatment scheme for castrate-resistant prostate cancer.
P atients with castrate-resistant prostate cancer are living longer with a defined natural history in most cases. As such, efforts to develop new therapeutic modalities that are as equally efficacious as androgen receptor (AR)-directed therapy and chemotherapy and have fewer adverse effects are ongoing. Over the last decade, cabazitaxel (Jevtana), 1 sipuleucel-T (Provenge), 2 abiraterone (Zytiga), 3 enzalutamide (Xtandi), 4 and radium-223 (Xofigo) 5 have been approved for the treatment of men with castration-resistant prostate cancer based on evidence of improved overall survival (OS). Of these, only sipuleucel-T is an immunotherapeutic agent. Cancer immunotherapy can be broadly classified as therapeutic cancer vaccines, 6 checkpoint inhibitors, 7 or adoptive cellular therapy. 8 Unlike cytotoxic chemotherapy and androgen deprivation therapy, which act directly against the tumor, immunotherapy attempts to recruit the host's immune system to recognize the tumor as foreign and reject the tumor through direct cytolytic effect. Vaccine-based immunotherapy relies on the innate ability of antigen-presenting cells (APCs) to capture and process antigens for display to T cells. These APCs can be harnessed to capture and present one or more prostate cancer tumor-associated antigens (TAAs) leading to the generation of a humoral and cytotoxic T-cell response to the cancer (Fig. 1) . Checkpoint inhibition relies on T cells that already recognize the TAA but have been inhibited either by signals intended to prevent autoimmunity or by a suppressive tumor microenvironment. These drugs act by uncoupling inhibitory signals or "brakes" to facilitate full T-cell activation (Fig. 2) . Adoptive transfer of engineered T cells obviates the need for APCs or endogenous TAA-recognizing T cells and instead relies on engineered synthetic single-chain variable fragments (scFv) that recognize the TAA in an human leukocyte antigen-independent fashion to facilitate T cell-mediated cytotoxicity ( Fig. 3) . Research into the mechanisms of action of these immunotherapeutic agents and how to best integrate them into current treatment paradigms of castrate-resistant prostate cancer (CRPC) management is continuing. This review discusses promising immune therapy agents, their mechanisms of action, and current approaches to combination therapy with chemotherapy, radiation, and AR-directed therapy.
SIPULEUCEL-T
Sipuleucel-T (Provenge) is currently the only approved cellular product immune therapy for the treatment of patients with asymptomatic or minimally symptomatic castrate-resistant prostate cancer. 6 Sipuleucel-T is an autologous product derived from ex vivo coincubation of a patient's peripheral blood mononuclear cells and APCs with a recombinant fusion protein consisting of prostatic acid phosphatase (PAP) and granulocyte-macrophage colony-stimulating factor (GM-CSF), collectively referred to as PA2024 9 (Fig. 1, top panel) . This ex vivo modified product is administered intravenously every 2 weeks apart for a total of 3 doses. The US Food and Drug Administration (FDA) approval of sipuleucel-T was based on a multicenter, double-blind, placebocontrolled phase III trial published by Kantoff et al. 2 showing improved OS in treated patients (Table 1) . Patients treated with sipuleucel-T had an increased mean OS by 4.1 months compared with the placebo-treated group (25.8 vs. 21.7 months). Despite improvement in OS, time to clinical (hazard ratio [HR], 0.92; 95% confidence interval [CI], 0.75-1.12; P = 0.40) and objective disease progression (HR, 0.05; 95% CI, 0.77-1.17; P = 0.63) was similar between the treatment and placebo groups. Consistent with a vaccination response, antibody titers to the immunogen and PAP were increased in the sipuleucel-T group as well as T-cell proliferation index after 6 weeks, suggestive of a persistent pool of T cells that recognized the antigen. Another phase III study by Small et al. 10 also did not show any differences in time to progression but did show an OS benefit of 4.5 months.
Mechanism of Action
In an effort to understand the mechanism of sipuleucel-T efficacy, Sheikh et al. 11 performed a detailed characterization of the postactivated immune cells subsets, posttreatment humoral compartment, T-cell activation, and cytokine analysis of patients treated on 3 phase III trials. After ex vivo coculture with the fusion protein PA2024, the autologous derived product was rich in CD14 + APCs, CD3 + T cells, CD56 + natural killer cells, and a minority of CD19 + B cells. ELISPOT assays also demonstrated increased PA202-specific T-cell proliferation and interferon γ production. Supernatants from the PA2024-treated product had increased cytokines such as interleukin 2 (IL-2), IL-12, tumor necrosis factor α, and interferon γ. 11 In vivo, patients treated with sipuleucel-T showed cellular and humoral responses against PA2024 and or PAP. While the data on the improved OS with sipuleucel-T have been replicated, the absence of a clear mechanism of action has led to critiques on the experimental design, 12 specifically the absence of a control arm that includes a GM-CSF-expressing construct alone without the fused antigen product. Activated dendritic cells secrete GM-CSF, and GM-CSF has been suggested to have antitumor activity based on a phase II clinical trial showing prostate-specific antigen (PSA) responses in patients with castrate-resistant prostate cancer treated with exogenous GM-CSF. 13 Another hypothesis for the mechanism of action of sipuleucel-T involves modification or reshaping of the immune landscape. Analysis of patient samples from the IMPACT trial revealed evidence of significantly elevated serum immunoglobulin G (IgG) levels at weeks 2, 10, and 22. 14 Furthermore, these IgG molecules were directed against prostate cancer TAAs. Some of these antigens were confirmed by Luminex xMAP and included PSA, KLK2, E-ras, and K-ras. None of these antigens were included in the PA202 fusion protein. Taken together with data from McNeel et al., 15 which showed increased polyclonal gamma globulins, these findings are suggestive of antigen CD4 + FoxP3 + T cells at the tumor interface. Despite elevated programmed cell death protein 1 (PD-1) expression in the infiltrating CD3 + T cells, equally elevated Ki67 suggested that elevated PD-1 was more a marker of T-cell activation than exhaustion. It should be noted, however, that despite being on a continuum, hormonesensitive prostate cancer and castrate-resistant metastatic prostate cancer are biologically distinct entities, 19 and as such, the results of this study may not be applicable to castrate-resistant disease. 10 Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer Median OS 25.9 vs. 21.4 mo (HR, 1.70; 95% CI, 1.13-2.56; P = 0.01) Time to disease progression 11.7 vs. 10 wk (HR, 1.45; 95% CI, 0.99-2.11; P = 0.052) Kantoff et al. 27 Phase II randomized controlled trial of PROSTVAC-VF in metastatic castration-resistant prostate cancer Median OS 25.1 vs. 16.6 mo (HR, 0.56; 95% CI, 0.37-0.85; P = 0.0061)* Median progression-free survival 3.8 vs. 3.7 mo (HR, 0.88; 95% CI, 0.57-1.38; P = 0.60) † Slovin et al. 43 Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study Median OS 17.4 mo (95% CI, 11.5-24.7 mo)
PSA decline >50% in 8 (16% patients at 10-mg/kg dose ± radiation; 1 patient had CR, and 6 patients had SD Kwon et al. 44 Multicenter, randomized phase III trial of ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel Median OS 11.2 mo for ipilimumab group vs. 10 mo for placebo (HR, 0.85; 95% CI, 0.72-1.00; P = 0.05)
Increased progression-free survival of 4 mo for ipilimumab group vs. 3.1 mo for placebo (HR, 0.70; 95% CI, 0.61-0.82; P < 0.0001) *OS was not the primary prespecified endpoint. †Treatment versus placebo. CR indicates complete response; SD, stable disease.
Enhancing Efficacy
Sipuleucel-T is generally well tolerated. 9 The most common adverse effects were grade 1 or 2 chills, fever, fatigue, nausea, and headache, with most of these reactions occurring within 1 to 2 days following infusion. 2 Despite a survival benefit, it remains unclear how long a patient should be observed to determine whether there is an antitumor effect. Radiographic and biochemical responses to the treatment have been suboptimal; therefore, it is reasonable to combine sipuleucel-T with other FDA-approved agents. Kantoff et al. 2 reported improved OS attributable to sipuleucel-T in the patients who went on to receive docetaxel chemotherapy. Intriguing as these findings are, there are no currently active clinical trials exploring the combination of sipuleucel-T and chemotherapy. This is perhaps due in part to the rationale that newer agents such as sipuleucel-T are envisioned to delay or avoid the use of chemotherapy in men with castrate-resistant prostate cancer. Abiraterone is an orally bioavailable potent CYP17 inhibitor that significantly lowers circulating testosterone levels and is approved for the management of castrate-resistant prostate cancer based on phase III clinical trials showing improved PFS and OS. 3 Small and colleagues 20 recently published the results of a phase II clinical trial examining the safety and immunological profile of patients treated with sipuleucel-T and either sequentially or concurrently with abiraterone. In the concurrent treatment arm, abiraterone was started 1 day after the first sipuleucel-T infusion, and in the sequential arm, abiraterone was started 6 weeks after the third infusion of sipuleucel-T. Treatment was well tolerated in both arms, with muscle spasms, fatigue, back pain, and nausea being the most adverse effects reported. The authors reported ex vivo APC activation and comparable in vivo cellular and humoral responses between both arms. There were no differences in IgG levels against PSA and LGALS3 between both arms. Patients from both arms had a PSA decline of 50% or greater, and the percentage of patients responding in the concurrent and sequential treatment arms was not statistically significant (65.7% vs. 58.8%; P = 0.6624). This report suggests that abiraterone can be combined with sipuleucel-T without compromising efficacy. A case report of a single patient with CRPC with metastasis to the bone responding to the addition of sipuleucel-T to enzalutamide has also been reported. 21 
Perspectives
There are several currently active or recruiting clinical trials looking at the combination of sipuleucel-T and radiation therapy (NCT01807065, NCT01833208), radium-223 (NCT02463799), anti-PD-1 antibody (NCT01420965), cytotoxic T-lymphocyteassociated protein 4 (CTLA-4) blockade (NCT01804465), recombinant IL-7 (NCT01881867), and indoleamine 2,3-dioxygenase inhibitors (NCT01560923). Combining sipuleucel-T with radiation therapy or radium-223 might generate neoantigens that can be captured by APCs that have been primed by sipuleucel-T therapy. Alternatively, the efficacy of "educated" T cells might be further improved with the addition of CTLA-4 inhibitors, or cytokine therapy to sipuleucel-T therapy. As these trials result, clinical correlates and translational research will provide more insight into the mechanism of sipuleucel-T activity and help refine its role in the algorithm of management of men with castrate-resistant prostate cancer.
PSA-TRICOM
PSA-TRICOM (Prostvac) is a peptide antitumor vaccine utilizing a prime boost regimen based on a recombinant vaccinia vector containing PSA, B7.1, ICAM-1, and LFA3 (TRICOM) as the prime, followed by a fowlpox PSA-TRICOM vector as the boost. 22, 23 Similar to the mechanism of action of many vaccines, the PSA-TRICOM viral construct is expected to infect dendritic cells and other immune cells whereupon the PSA and TRICOM costimulatory molecules are presented by the APC to effector T cells 24 (Fig. 1, bottom panel) . A phase I study by DiPaola et al. 23 reported 10 patients treated with 1 dose of vaccinia PSA-TRICOM on day 1 followed by another dose of fowlpox PSA-TRICOM on day 29. Examination for toxicity performed on day 57 showed that the treatment was well tolerated, with injection site reactions and fatigue being the most common adverse effects. In another phase I trial by Arlen and colleagues, 25 3 doses of fowlpox PSA-TRICOM boosts with or without vector-based or recombinant GM-CSF were evaluated. Similar to the prior phase I study, PSA-TRICOM was well tolerated, with injection site reactions, sweating, and bone pain being the most common reactions, the latter of which is likely due to GM-CSF administration. A phase II randomized study in patients with chemotherapy naive metastatic CRPC randomized to receive PSA-TRICOM with or without vector-based or recombinant GM-CSF 26 has been reported. The authors reported "absolute" PSA declines in 12 (37.5%) of 32 patients, durable PSA response of greater than 50% in 1 patient for over 30 months, and 2 objective responses as assessed by regression of a soft tissue mass and lymphadenopathy. Kantoff et al. 27 conducted a double-blind, placebo-controlled trial with PSA-TRICOM and recombinant GM-CSF. Patients with visceral metastasis or symptomatic disease were excluded from study participation. Prostate-specific antigen responses were infrequent on this study, with only 1 patient achieving a greater than 80% PSA decline. There were no lymph node regressions, and at 180 days, 23% of the patients of the patients in the control arm and 25% of the patient in the treatment arm had progressed. Median OS was increased in the treatment arm compared with the placebo-treated cohort (25.1 vs. 16.6 months; HR, 0.56; P = 0.0061). A phase III randomized clinical trial in men with CRPC is completed and pending analysis (NCT01322490).
Mechanism of Action
Examination of immune responses before and after vaccination did not reveal any differences in PSA-specific T-cell responses among patients treated with PSA-TRICOM and either vector-based or recombinant GM-CSF. 26 In a separate report, a detailed quantitative and qualitative regulatory T cell (Treg) analysis was performed on patient samples. 28 The authors did not find any significant differences in CD4 + CD25 + FoxP3 + Treg numbers in patients with improved OS. However, most patients with improved OS had decreased Treg suppressive activity. Despite elaboration of antibody responses to vaccinia, no humoral response to PSA was observed by Kantoff et al. 27 There is speculation that similar to sipuleucel-T, PSA-TRICOM improves OS by altering tumor growth dynamics. 29 It has also been proposed that perhaps PSA response and progression-free survival are not adequately suited to measuring response in vaccine-based immunotherapy. 29 In contrast to these studies, Jochems et al. 30 reported differences in T-cell populations in patients treated with combination PSA-TRICOM and ipilimumab (Yervoy). However, the additive or synergistic effect of ipilimumab makes it challenging to attribute which treatment led to what finding. As previously mentioned, PSA-TRICOM is well tolerated, which lends well to combinatorial therapy due to a reduced risk for additive toxicities.
Enhancing Efficacy
In the absence of robust effector T-cell activity in patients treated with PSA-TRICOM, combination with checkpoint blockade is a rational choice. Madan et al. 31 conducted a phase I dose escalation study of PSA-TRICOM in patients with metastatic CRPC, the majority of whom had not had previous chemotherapy (24/30) . Treatment was generally well tolerated with only a few cases of grade 3/4 colitis, rash, and endocrinopathies likely related to ipilimumab therapy. Of the patients who had not received prior chemotherapy, 25% (6/24) had a PSA decline greater than 50% from baseline, and 58% had PSA decrease from baseline. In patients who had previous chemotherapy exposure, only 1 (of 6) had a PSA decline from baseline. Because this was a safety and tolerability trial, phase II trials are needed to explore efficacy.
Perspectives
The role of PSA-TRICOM in the algorithm of metastatic CRPC management is yet to be defined. Combining chemotherapy with PSA-TRICOM both might lead to a rapid antitumor response and could potentially augment the vaccination effect via elaboration of neoantigens upon tumor lysis. Furthermore, androgen ablation has been reported to reverse T-cell tolerance 32 and positively augment vaccine responses. 33 Clinical trials exploring combination therapy with docetaxel (NCT02649855) and enzalutamide (NCT01867333) are ongoing.
IPILIMUMAB
Checkpoint blockade has been collectively used to describe CTLA-4 inhibitors, PD-1, and PD-1 ligand inhibitors. Checkpoint inhibitors were catapulted into therapeutic relevance based on data showing improved progression-free and OS in patients with metastatic melanoma treated with ipilimumab (Yervoy). 34 Further evidence to support efficacy for this class of drugs came with the approval of nivolumab (Opdivo) in metastatic melanoma 35 and non-small cell lung cancer 36, 37 and more recently renal cell cancer 38 and with pembrolizumab (Keytruda) for non-small cell lung cancer. 39 The first agent in this class and perhaps the most studied is ipilimumab, an anti-CTLA-4 inhibitor. CTLA-4 is expressed on activated T cells. 7 CD80 (B7.1) is expressed on APCs and binds to its cognate receptor CD28 on T cells. This interaction provides an important costimulatory signal for T-cell activation. CTLA-4 also binds to CD80 but instead provides an inhibitory signal. Ipilimumab binds to CTLA-4 and inhibits the interaction between CTLA-4 and CD80, thereby abolishing this negative regulation and promoting a persistent T-cell activation 7 (Fig. 2) . Achievement of a durable response, especially in patients with metastatic melanoma treated with ipilimumab, 40 has prompted intensive investigation into its efficacy in prostate cancer. Small et al. 41 treated 14 patients with castrate-resistant prostate cancer with a single 3-mg/kg dose of ipilimumab. Only 2 of these patients had a PSA response, defined as a PSA decline of 50% or greater. Both of these patients were retreated upon relapse, but there were no further responses. A phase II study of patients with chemotherapy-naive castration-resistant prostate cancer treated with 4 doses of ipilimumab given every 4 weeks and another arm that included a single dose of docetaxel was presented. 42 Although there were no radiographic responses, 3 patients in each treatment arm had a PSA response of 50% or greater. In another phase I/II report by Slovin et al., 43 71 patients were treated with either ipilimumab alone or ipilimumab and external beam radiation therapy. Of 11 patients who received ipilimumab alone, 6 had a PSA decline of 50% or greater. Although there were some serious adverse immune-related toxicities reported in the trial, the authors were able to reach the prespecified maximum dose of 10 mg/kg. The median OS was 17.4 months (95% CI, 11.5-24.7 months). The only published phase III trial for ipilimumab was conducted by Kwon et al. 44 In this 799 patient multicenter clinical trial, patients with castrate-resistant prostate cancer with at least 1 bone metastasis were randomized to receive either ipilimumab (10 mg/kg every 3 weeks) or placebo after radiation. The prespecified primary endpoint was OS. The 6-month progression-free survival was superior in the ipilimumab treatment group compared with placebo (30.7% [95% CI, 26.0%-35.3%] vs. 18.1% [14.2%-22.0%]), and the frequency of PSA responses was greater in the ipilimumab arm as well (13.1% vs. 5.2% [95% CI, 9.5%-17.5%] vs. 3.0%-8.4%). However, the primary endpoint of OS was not met (ipilimumab: 11.2 months [95% CI, 9.5-12.7 months] vs. placebo: 10.0 months [95% CI, 8.3-11.0 months]; HR, 0.85; 95% CI, 0.72-1.00; P = 0.053). Subgroup analysis suggested that patients with no visceral metastasis, low bone alkaline phosphatase (<1.5Â upper limit of normal), and higher hemoglobin (>11.0 g/dL) were more likely to benefit from ipilimumab therapy. These findings are thought provoking but ultimately can be interpreted only as hypothesis generating. A randomized phase III trial in patients with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer who have not had previous chemotherapy has completed, and results are eagerly anticipated (NCT01057810).
Mechanism of Action
The reason ipilimumab works in some solid tumors but not others is currently an area of intense investigation. Differences in doses and concurrent treatments (i.e., docetaxel, EBRT) have made cross-trial comparisons challenging in prostate cancer ipilimumab trials. T-cell infiltration has been reported in prostatectomy samples, 45 and CD4 + CD25 + FoxP3 + Tregs have also been found in high numbers in peripheral blood and prostatectomy samples. 46 It has been hypothesized that these infiltrating effector T cells are suppressed by neighboring Tregs. Preclinical in vivo models in mice show quite elegantly that prostate cancer cell lines modified to express the CTLA-4 cognate receptor B7 are rejected by the host's immune system. 47 In this model, treatment of wildtype prostate cancer cell lines with anti-CTLA-4 antibodies led to significant growth inhibition or outright tumor eradication. Extended to a mouse model of residual disease after surgical resection, anti-CTLA-4 antibodies significantly decreased relapse after resection of the primary tumor by eradicating residual nodal metastasis after surgery. 48 The weight of this preclinical evidence makes the failure of ipilimumab in prostate cancer clinical trials all the more perplexing. A detailed characterization of the immunological landscape after ipilimumab treatment was reported by Jochems et al. 30 This report examined immune correlates of patients treated with a single dose of PSA-TRICOM and escalating doses of ipilimumab. A PSA response was reported in 25% (6/24) of treated patients. Comparison of cellular immunophenotypes at baseline and up to 13 and 70 days after treatment showed a positive correlation between increased activated CD8 T cells (PD-1 Neg TIM-3 + CD8 + ), lower effector memory CD4 T cells (PD-1 + TIM-3 NEG CD4 EM ), increased mature natural killer cells (CD16 + CD56 DIM ), and lower Tregs (CD4 + CD25 Hi FoxP3 + CD127 NEG ) with an increase in OS. 30 One caveat in the interpretation of this study is that vaccination therapy was also used; this might confound delineation of the effects of ipilimumab alone on modulation of the immunophenotypic landscape. Although correlative in nature, identification of an immunophenotypic profile that correlates with survival might one day be used as a tool to identify patients who might benefit in the long term from ipilimumab. Lessons learned from this and other correlative studies can then be retroactively applied to preclinical animal models to better understand why ipilimumab works for some patients and more importantly how it can be improved.
Enhancing Efficacy
Because of the unique mechanism of action of ipilimumab, clinical trials evaluating synergy between ipilimumab and radiation, 43, 44 PSA-TRICOM, 31 GVAX, 49 and docetaxel 42 have been explored. However, one of the primary concerns regarding ipilimumab has been its adverse effect profile. 50 These so-called immune-related adverse events include grade 3 rash, dizziness, and asthenia at the 3-mg/kg dose. 41 In 1 trial involving a single dose of radiation therapy and 10 mg/kg of ipilimumab, 43 there was significant grade 3/4 diarrhea, colitis, and hepatitis, including 1 treatment-related mortality at the 5-mg/kg dose secondary to sepsis. Notably in this trial, there was 1 patient who achieved a complete and durable remission. The phase III trial by Kwon et al. 44 also involving radiation reported 4 treatment-related mortalities and 5 gastrointestinal perforations in addition to colitis, rash, and pruritus. Although it is tempting to draw an association with the use of radiotherapy and increased severity of the adverse events reported in these trials, similar immune-related toxicities have been observed in melanoma clinical trials, and these patients did not receive radiation therapy. 50 Similarly, colitis, rash, adrenal insufficiency, and panhypophysitis have been reported in the vaccine combination arms. 31, 49 Prompt recognition and intervention have mitigated many of the on-target, off-tumor toxicities reported in the early trials of ipilimumab therapy.
Perspectives
Despite some of the setbacks with checkpoint blockade therapy for prostate cancer in general and for ipilimumab in particular, efforts are ongoing to determine which combination of available or novel agents will synergize with ipilimumab. Currently, there are trials exploring the role of combining immediate or delayed CTLA-4 inhibition with sipuleucel-T (NCT01804465), combination ipilimumab and nivolumab (NCT02601014), and MGA271, a novel monoclonal antibody directed against B7-H3, in combination with ipilimumab in patients with castrate-resistant prostate cancer (NCT02381314). Clinical trials exploring PD-1 inhibition in prostate cancer are also currently in progress (NCT01420965, NCT02499835, NCT02312557, NCT02475213).
CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY
Chimeric antigen receptor (CAR) T cells are autologous T cells that have been engineered ex vivo to express a CAR directed against a TAA 51 (Fig. 3 ). Chimeric antigen receptor T cells consist of a synthetic T-cell receptor or single-chain variable fragment (scFv) consisting of the variable regions of an antibody heavy and light chain directed against a TAA. This sequence is followed by 1 or more signaling domains designed to facilitate T-cell activation. Inclusion of the cluster of differentiation 3ς (CD3ς) signaling domain provides activation signal 1 that is necessary, but not sufficient for complete T-cell activation. Chimeric antigen receptor T cells with this design are designated "first-generation" CAR-T cells, and while they showed promising preclinical efficacy in hematologic malignancy tumor models, 52 they were largely ineffective in subsequent clinical trials. 53 Attempts to improve on this design involve engineering CD28 in series with CD3ς to provide the important signal 2 necessary to avoid activation-induced cell death in CAR-T cells. These second-generation CAR-T cells have shown great promise in the management of B-cell hematologic cancers. 54 Other molecules such as 4-1BB have been used to provide signal 2, 55 and combinations of 3 costimulatory molecules have been engineered to generate third-generation CAR-T cells. 56 In addition, CAR-T cells can be further modified to secrete cytokines or express ligands that further enhance their antitumor efficacy. 57 Overall, CAR-T cell therapy has not had the same success in the management of solid tumor malignancies, 58 and this therapy is not yet approved for the management of any solid or hematologic malignancy. Junghans et al. 59 reported a PSA response in 2 of 5 patients treated with first-generation prostate-specific membrane antigen-directed (PSMA) CAR-T cells. This approach required nonmyeloablative preconditioning and concurrent IL-2 administration. Second-generation and armored CAR-T cells have been designed to reduce or eliminate the requirement for preconditioning and continuous cytokine administration. A phase I dose escalation trial of PSMA-directed, second-generation CAR-T cells has recently concluded (NCT01140373).
Mechanism of Action
The 2 most commonly utilized TAAs for prostate cancer CAR-T cell therapy are PSMA 56 and PSCA (prostate stem cell antigen) 60 because of their relatively restricted expression to the tumor and tumor-associated vasculature. Hillerdal et al. 60 reported robust PSCA-directed, third-generation (CD3ς/CD28/OX40) CAR-T cell proliferation and surface expression of surrogate degranulation markers (CD107a) when exposed to PSCA-expressing tumor cells. Furthermore, treatment of tumor-bearing mice with PSCA-directed CAR-T cells led to impaired tumor growth and improved OS in a xenograft model. In another report using PSMA-directed, third-generation CAR-T cells (CD3ς/CD28/4-1BB), Zhong et al. 56 showed significantly improved OS compared with second-generation, PSMA-directed CAR-T cells. Chimeric antigen receptor T cell therapy is generally well tolerated based on inferred data from hematologic malignancy clinical trials. However, cytokine release syndrome (CRS), characterized by fever, myalgias, flu-like symptoms, encephalopathy, and even seizures, has been reported. 61 Furthermore, there has been a correlation between disease burden at the time of treatment and the severity of CRS. 61 Because of the paucity of ongoing clinical trials for CAR-T cell therapy in solid tumors, the likelihood and potential severity of CRS are unknown. In addition, it is unclear if the correlation between disease burden and CRS severity will be similar between solid and hematologic malignancies.
Enhancing Efficacy
Clinical trials examining combination therapy with CAR-T cells are forthcoming, likely pending results of maximum tolerated dose, requirement for chemotherapy preconditioning, and safety from the soon-to-be-resulted phase I trial. There is suggestion, however, that combination with anti-PD-1 checkpoint blockade can enhance CAR-T cell therapy. 62 This synergy was found to be partly due to increased proliferation and function of CAR-T cells in addition to decreased PD-1 expressing myeloid derived suppressor cell at the tumor. Whether this rationally designed combination can be extended to prostate cancer is a question yet to be answered.
Perspectives
Chimeric antigen receptor T cell therapy for prostate cancer is in its clinical infancy compared with tumor vaccines or checkpoint inhibitors. Besides the aforementioned phase I trial in patients with castrate-resistant prostate cancer (NCT01140373), there is only 1 other trial in patients with advanced castrateresistant prostate cancer after nonmyeloablative conditioning (NCT00664196). There is rationale for combining CAR-T cell therapy with checkpoint blockade, AR-directed therapy, or cytotoxic chemotherapy in an effort to augment CAR-T cell efficacy, decrease tumor burden, or facilitate antigen spreading. These avenues can be explored once optimal CAR-T cell dose and singleagent efficacy are established.
